Compare Sirius XM Holdings Inc (SIRI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs Viatris Inc — how do they compare? Sirius XM Holdings Inc trades at $30.27 (market cap $10.30B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays the higher dividend (3.53%). Which is the better fit depends on your goals.
| SIRI | VTRS | |
|---|---|---|
Market Cap | $10.30B | $19.79B |
Sector | Media | Health |
52-Week High | $31.22 | $17.39 |
52-Week Low | $19.92 | $8.74 |
Enterprise Value | $19.97B | $32.00B |
Dividend Yield | 3.53% | 2.83% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
